{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:46:36Z","timestamp":1775522796794,"version":"3.50.1"},"reference-count":164,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunoepigenetics is a growing field, as there is mounting evidence on the key role played by epigenetic mechanisms in the regulation of tumor immune cell recognition and control of immune cell anti-tumor responses. Moreover, it is increasingly acknowledgeable a tie between epigenetic regulation and prostate cancer (PCa) development and progression. PCa is intrinsically a cold tumor, with scarce immune cell infiltration and low inflammatory tumor microenvironment. However, Natural Killer (NK) cells, main anti-tumor effector immune cells, have been frequently linked to improved PCa prognosis. The role that epigenetic-related mechanisms might have in regulating both NK cell recognition of PCa tumor cells and NK cell functions in PCa is still mainly unknown. Epigenetic modulating drugs have been showing boundless therapeutic potential as anti-tumor agents, however their role in immune cell regulation and recognition is scarce. In this review, we focused on studies addressing modulation of epigenetic mechanisms involved in NK cell-mediated responses, including both the epigenetic modulation of tumor cell NK ligand expression and NK cell receptor expression and function in different tumor models, highlighting studies in PCa. The integrated knowledge from diverse epigenetic modulation mechanisms promoting NK cell-mediated immunity in various tumor models might open doors for the development of novel epigenetic-based therapeutic options for PCa management.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1152572","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T05:12:15Z","timestamp":1680671535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity"],"prefix":"10.3389","volume":"14","author":[{"given":"Filipa D.","family":"dos Reis","sequence":"first","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"given":"Margareta P.","family":"Correia","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20132020 update. part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II\u20132020 update: Treatment of relapsing and metastatic prostate Cancer[Formula presented]","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842038","article-title":"Angiogenesis as therapeutic target in metastatic prostate cancer \u2013 narrowing the gap between bench and bedside","volume":"13","author":"Solimando","year":"2022","journal-title":"Front Immunol"},{"key":"B7","unstructured":"van MoorselaarRJA\n            VoestEE\n          Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms20112676","article-title":"Targeting angiogenesis in prostate cancer","volume":"20","author":"Melegh","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.652747","article-title":"Tumor microenvironment in prostate cancer: Toward identification of novel molecular biomarkers for diagnosis, prognosis, and therapy development","volume":"12","author":"Bahmad","year":"2021","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02527-6","article-title":"Neutrophils are mediators of metastatic prostate cancer progression in bone","volume":"69","author":"Costanzo-Garvey","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08405-3","article-title":"Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1701-6","article-title":"High preoperative neutrophil\u2013lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy","volume":"34","author":"Lee","year":"2016","journal-title":"World J Urol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07382-3","article-title":"Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3614-9","article-title":"The values of neutrophil-lymphocyte ratio and\/or prostate-specific antigen in discriminating real Gleason score\u22657 prostate cancer from group of biopsy-based Gleason score \u2264 6","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu587","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use","volume":"26","author":"Lorente","year":"2015","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1637","article-title":"Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers","volume":"71","author":"Pittoni","year":"2011","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603962","article-title":"Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer","volume":"97","author":"Nonomura","year":"2007","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0962","article-title":"High extratumoral mast cell counts are associated with a higher risk of adverse prostate cancer outcomes","volume":"29","author":"Sullivan","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy141","article-title":"The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target","volume":"111","author":"Zhao","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100070","article-title":"Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy","volume":"177","author":"Johansson","year":"2010","journal-title":"Am J Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep15651","article-title":"Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions","volume":"5","author":"Lundholm","year":"2015","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23742","article-title":"M2 macrophages and regulatory T cells in lethal prostate cancer","volume":"79","author":"Erlandsson","year":"2019","journal-title":"Prostate"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4463","article-title":"Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms","volume":"24","author":"Bezzi","year":"2018","journal-title":"Nat Med"},{"key":"B24","article-title":"Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy","volume":"3","author":"Gollapudi","year":"2013","journal-title":"Am J Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/path.5757","article-title":"Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors","volume":"255","author":"Andersen","year":"2021","journal-title":"J Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.191","article-title":"Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression","volume":"33","author":"Comito","year":"2014","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0060","article-title":"Prostate epithelial RON signaling promotes M2 macrophage activation to drive prostate tumor growth and progression Camille","volume":"18","author":"Sullivan","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18313-y","article-title":"Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion","volume":"11","author":"Cioni","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.02.009","article-title":"Regulation of immunophenotype modulation of monocytes-macrophages from M1 into M2 by prostate cancer cell-culture supernatant via transcription factor STAT3","volume":"196","author":"Sol\u00eds-Mart\u00ednez","year":"2018","journal-title":"Immunol Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15541","article-title":"Macrophages expedite cell proliferation of prostate intraepithelial neoplasia through their downstream target ERK","volume":"288","author":"Thomas","year":"2021","journal-title":"FEBS J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21369","article-title":"Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 loop","volume":"71","author":"Lee","year":"2011","journal-title":"Prostate"},{"key":"B32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","article-title":"CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling","volume":"11","author":"Huang","year":"2020","journal-title":"Cell Death Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5808962","DOI":"10.1155\/2018\/5808962","article-title":"Prostaglandin E2 inhibits prostate cancer progression by countervailing tumor microenvironment-induced impairment of dendritic cell migration through LXR\u03b1\/CCR7 pathway","volume":"2018","author":"Youlin","year":"2018","journal-title":"J Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20013078.2017.1368823","article-title":"Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes","volume":"6","author":"Salimu","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1591-2","article-title":"Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer","volume":"63","author":"Idorn","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0266-0.IL23","article-title":"IL23 secreted by myeloid cells drives castration resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2019","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0003","article-title":"Infiltrating myeloid cells exert pro-tumorigenic actions via neutrophil elastase","volume":"15","author":"Lerman","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discovery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3145","article-title":"TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients","volume":"21","author":"Hossain","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.517637","article-title":"The landscape of immune cells infiltrating in prostate cancer","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24068","article-title":"High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy","volume":"81","author":"Yang","year":"2021","journal-title":"Prostate"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2804","article-title":"Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients","volume":"17","author":"Sorrentino","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-01900-4","article-title":"CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer","volume":"11","author":"Yanai","year":"2021","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22862","article-title":"Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer","volume":"74","author":"Ness","year":"2014","journal-title":"Prostate"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.05.013","article-title":"PD-L1 expression and CD8 + T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer","volume":"5","author":"Petitprez","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molonc.2014.07.013","article-title":"Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11\u2192miRNA-541\u2192androgen receptor (AR)\u2192MMP9 signaling","volume":"9","author":"Hu","year":"2015","journal-title":"Mol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pros.20661","article-title":"Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma","volume":"68","author":"Ebelt","year":"2008","journal-title":"Prostate"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.02.015","article-title":"Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters","volume":"45","author":"Ebelt","year":"2009","journal-title":"Eur J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24315","article-title":"Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer","volume":"82","author":"Ozbek","year":"2022","journal-title":"Prostate"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1752-y","article-title":"Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression","volume":"64","author":"Japp","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.09.003","article-title":"Positive pelvic lymph nodes in prostate cancer harbor immune suppressor cells to impair tumor-reactive T cells","volume":"4","author":"Sharma","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.04.019","article-title":"T Cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-\u03b21 cytokine","volume":"35","author":"Donkor","year":"2011","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00930","article-title":"Immune cytolytic activity as an indicator of immune checkpoint inhibitors treatment for prostate cancer","volume":"8","author":"Gao","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28026","article-title":"Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer","volume":"133","author":"Huen","year":"2013","journal-title":"Int J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23808","article-title":"PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells","volume":"79","author":"Vidotto","year":"2019","journal-title":"Prostate"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5164","article-title":"Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH 17 and treg skewing","volume":"14","author":"Sfanos","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23890","article-title":"Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis","volume":"79","author":"Watanabe","year":"2019","journal-title":"Prostate"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32803","article-title":"Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer","volume":"147","author":"Laheurte","year":"2020","journal-title":"Int J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.035","article-title":"High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer","volume":"49","author":"Flammiger","year":"2013","journal-title":"Eur J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1235666","article-title":"Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse","volume":"17","author":"Nardone","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-12-30","article-title":"Tumor infiltrating b-cells are increased in prostate cancer tissue","volume":"12","author":"Woo","year":"2014","journal-title":"J Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature08782","article-title":"B cell\u2013derived lymphotoxin promotes castration-resistant prostate cancer","volume":"464","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69369","article-title":"Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis","volume":"123","author":"Liu","year":"2013","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3965","article-title":"Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer","volume":"6","author":"Pasero","year":"2015","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2567.2011.03513.x","article-title":"Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3","volume":"135","author":"Park","year":"2012","journal-title":"Immunology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.035","article-title":"Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7)","volume":"398","author":"Lin","year":"2017","journal-title":"Cancer Lett"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0078049","article-title":"Reduction of the CD16-CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer","volume":"8","author":"Koo","year":"2013","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586126","article-title":"Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1371\/journal.pone.0108925","article-title":"Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: Mechanism of immune evasion","volume":"9","author":"Lundholm","year":"2014","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1429-z","article-title":"NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis","volume":"38","author":"Saga","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2013.458","article-title":"MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells","volume":"4","author":"Liu","year":"2013","journal-title":"Cell Death Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00884","article-title":"Past, current, and future of immunotherapies for prostate cancer","volume":"9","author":"Boettcher","year":"2019","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2020.1762473","article-title":"A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer","volume":"9","author":"Shao","year":"2020","journal-title":"Oncoimmunology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11736","article-title":"Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor (Review)","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol Lett"},{"key":"B77","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","article-title":"Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis","volume":"8","author":"Trabanelli","year":"2017","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/319675a0","article-title":"Selective rejection of h-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J Exp Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672328","article-title":"Epigenetic regulation of NK cell-mediated antitumor immunity","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.035","article-title":"Epigenetics in prostate cancer: Biologic and clinical relevance","volume":"60","author":"Jer\u00f3nimo","year":"2011","journal-title":"Eur Urol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13148-016-0264-8","article-title":"Epigenetic modulators as therapeutic targets in prostate cancer","volume":"8","author":"Gra\u00e7a","year":"2016","journal-title":"Clin Epigenet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.07.015","article-title":"Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress","author":"Neganova","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3390\/molecules26133952","article-title":"Differential effects of histone deacetylases on the expression of nkg2d ligands and nk cell-mediated anticancer immunity in lung cancer cells","volume":"26","author":"Cho","year":"2021","journal-title":"Molecules"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0073","article-title":"Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1452","article-title":"Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2\u2032-deoxycytidine treatment","volume":"94","author":"Serrano","year":"2001","journal-title":"Int J Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2099","article-title":"Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen","volume":"15","author":"Dubovsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006069","article-title":"Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large b-cell lymphomas through combination drug treatment","volume":"6","author":"Bourne","year":"2022","journal-title":"Blood Adv"},{"key":"B91","doi-asserted-by":"publisher","first-page":"32470","DOI":"10.1038\/srep32470","article-title":"Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells","volume":"6","author":"Son","year":"2016","journal-title":"Sci Rep"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA Methyltransferase inhibition upregulates responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02689.x","article-title":"Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours","volume":"123","author":"Manning","year":"2008","journal-title":"Immunology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0402-4","article-title":"Histone deacetylase inhibitors induce TAP, LMP, tapasin genes and MHC class I antigen presentation by melanoma cells","volume":"57","author":"Khan","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.109","article-title":"Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition","volume":"178","author":"Kitamura","year":"2007","journal-title":"J Urol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2011.08.004","article-title":"Impact of the hypomethylating agent 5-azacytidine on dendritic cells function","volume":"39","author":"Frikeche","year":"2011","journal-title":"Exp Hematol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","article-title":"Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade","volume":"38","author":"Qin","year":"2019","journal-title":"Oncogene"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701216","article-title":"Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma","volume":"128","author":"Murakami","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7180","article-title":"Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells","volume":"7","author":"Gameiro","year":"2016","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cellimm.2018.12.010","article-title":"Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma","volume":"336","author":"Hong","year":"2019","journal-title":"Cell Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PloS One"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1020","article-title":"Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non\u2013small cell lung cancer","volume":"7","author":"Adeegbe","year":"2017","journal-title":"Cancer Discovery"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1935-1","article-title":"Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro","volume":"66","author":"Wang","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44622","article-title":"HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment","volume":"11","author":"Kim","year":"2020","journal-title":"J Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA\u2013STING\u2013interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1712514114","article-title":"Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B121","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1144","article-title":"Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate","volume":"39","author":"Ch\u00e1vez-Blanco","year":"2011","journal-title":"Int J Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00569","article-title":"Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma\/delta T cells upon interaction with tumor cells","volume":"10","author":"Bhat","year":"2019","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482513","article-title":"Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells","volume":"122","author":"Fiegler","year":"2013","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.06.027","article-title":"Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells","volume":"272","author":"Schmudde","year":"2008","journal-title":"Cancer Lett"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1466018","article-title":"Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types","volume":"7","author":"Hicks","year":"2018","journal-title":"Oncoimmunology"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102857","article-title":"The oncoprotein ski acts as a suppressor of nk cell-mediated immunosurveillance in PDAC","volume":"12","author":"Ponath","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701671","article-title":"Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat","volume":"12","author":"Afolabi","year":"2021","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.117","article-title":"HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: Potential implications for the immunosurveillance of cancer","volume":"28","author":"L\u00f3pez-Soto","year":"2009","journal-title":"Oncogene"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J Leukoc Biol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.03.131","article-title":"Induction of MHC class I-related chain b (MICB) by 5-aza-2\u2032-deoxycytidine","volume":"370","author":"Tang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B134","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baragan\u00f5 Raneros","year":"2015","journal-title":"Genes Immun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802691115","article-title":"Inhibition of enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells","volume":"115","author":"Bugide","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B136","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3892\/or.2017.5773","article-title":"Inhibition of the HDAC\/Suv39\/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain a and b in cancer cells","volume":"38","author":"Nakajima","year":"2017","journal-title":"Oncol Rep"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa058","article-title":"Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma","volume":"22","author":"Bailey","year":"2020","journal-title":"Neuro Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2021.2016158","article-title":"CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition","volume":"11","author":"Liu","year":"2022","journal-title":"Oncoimmunology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of cMYC-IRF4-miR-125b interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.7150\/jca.69375","article-title":"BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/JLB.1RU0520-311R","article-title":"The functions of EZH2 in immune cells: Principles for novel immunotherapies","volume":"110","author":"Shao","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"161.e7","DOI":"10.1016\/j.urolonc.2017.10.028","article-title":"High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer","volume":"36","author":"Lobo","year":"2018","journal-title":"Urol Oncol: Semin Original Investigations"},{"key":"B143","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/j.biopha.2022.113031","article-title":"G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models","volume":"150","author":"Moreira-Silva","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B144","article-title":"Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid","volume":"6","author":"Shi","year":"2016","journal-title":"Am J Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1005782","article-title":"Histone deacetylase inhibitors enhance CD4 T cell susceptibility to NK cell killing but reduce NK cell function","volume":"12","author":"Pace","year":"2016","journal-title":"PloS Pathog"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep45266","article-title":"The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3","volume":"7","author":"Ni","year":"2017","journal-title":"Sci Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521740112","article-title":"Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity","volume":"112","author":"Yin","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-019-0278-9","article-title":"Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer","volume":"26","author":"Ramakrishnan","year":"2019","journal-title":"Cell Death Differ"},{"key":"B149","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/epi.23115","article-title":"DNA Demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells","volume":"8","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2013","journal-title":"Epigenetics"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02196","article-title":"Scaffolding LSD1 inhibitors impair NK cell metabolism and cytotoxic function through depletion of glutathione","volume":"11","author":"Bailey","year":"2020","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.000698","article-title":"Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells","volume":"293","author":"Cribbs","year":"2018","journal-title":"J Biol Chem"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6213","article-title":"Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome","volume":"6","author":"Sohlberg","year":"2015","journal-title":"Oncotarget"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.02.033","article-title":"Demethylating treatment suppresses natural killer cell cytolytic activity","volume":"46","author":"Gao","year":"2009","journal-title":"Mol Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25635","article-title":"Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation","volume":"128","author":"Schmiedel","year":"2011","journal-title":"Int J Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4253","article-title":"Crucial role of DNA methylation in determination of clonally distributed killer cell ig-like receptor expression patterns in NK cells","volume":"169","author":"Santourlidis","year":"2002","journal-title":"J Immunol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.molimm.2012.12.012","article-title":"Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions","volume":"54","author":"Kopp","year":"2013","journal-title":"Mol Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.11.001","article-title":"Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function","volume":"534","author":"Watters","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22168742","article-title":"Inhibition of whsc1 allows for reprogramming of the immune compartment in prostate cancer","volume":"22","author":"Want","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.1MA0321-155RR","article-title":"Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function","volume":"110","author":"Yu","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001141","article-title":"Enhanced calcium signal induces NK cell degranulation but inhibits its cytotoxic activity","volume":"208","author":"Li","year":"2022","journal-title":"J Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1073\/pnas.2102718118","article-title":"EZH2 inhibits NK cell\u2013mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner","volume":"118","author":"Bugide","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1204-x","article-title":"Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice","volume":"61","author":"Triozzi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4110\/in.2020.20.e14","article-title":"NK cell-based immunotherapies in cancer","volume":"20","author":"Shin","year":"2020","journal-title":"Immune Netw"},{"key":"B164","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1152572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T05:12:25Z","timestamp":1680671545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1152572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":164,"alternative-id":["10.3389\/fimmu.2023.1152572"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1152572","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"article-number":"1152572"}}